Cargando…

Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study

INTRODUCTION: Treatment with ritonavir-boosted protease inhibitors and nucleoside analogues frequently leads to rises in lipids, which might increase the cardiovascular risk. The aim of this study was to describe changes in lipid levels among HIV positive patients participating in the GARDEL study....

Descripción completa

Detalles Bibliográficos
Autores principales:	Cahn, Pedro, Andrade Villanueva, Jaime, Arribas, Jose, Gatell, Jose, Lama, Javier, Norton, Michel, Patterson, Patricia, Sierra Madero, Juan, Sued, Omar, Ines Figueroa, Maria, Jose Rolón, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224811/ https://www.ncbi.nlm.nih.gov/pubmed/25394061 http://dx.doi.org/10.7448/IAS.17.4.19554

Ejemplares similares

The Feasibility Of A Mobile Application To Improve Heart Failure Care In Suriname
por: Sairras, Shellice, et al.
Publicado: (2023)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

AVALIAÇÃO DO IMPACTO DAS FAKE NEWS NO ÂMBITO DA SAÚDE PÚBLICA EM TEMPOS DE PANDEMIA PELO NOVO CORONAVÍRUS EM ARACAJU
por: de Souza, Gabrielle Barbosa Vasconcelos, et al.
Publicado: (2022)

TRIAGEM COM EXAME DE PCR SARS COV‐2 DE PACIENTES ASSINTOMÁTICOS NA INTERNAÇÃO HOSPITALAR: DESCRIÇÃO DE RESULTADOS DE 6 MESES DE IMPLANTAÇÃO DE ÁREAS DE TRANSIÇÃO NUM HOSPITAL PRIVADO TERCIÁRIO
por: Selegatto, Glória, et al.
Publicado: (2021)

Érythème pigmenté fixe bulleux généralisé post-vaccination anti-SARS-CoV-2
por: Sueur, P., et al.
Publicado: (2022)

Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial
por: Tan, Darrell H. S., et al.
Publicado: (2019)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

Évaluation des patients atteints de polyarthrite rhumatoïde en téléconsultation pendant la première vague de Covid-19
por: Avouac, J., et al.
Publicado: (2021)

Carlos Gardel, el gran desconocido
por: Silva Cabrera, Erasmo
Publicado: (1967)

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials
por: Arribas, Jose, et al.
Publicado: (2014)

Clinical-epidemiological features of HIV-infected patients diagnosed at age of 50 years or older
por: Patterson, P, et al.
Publicado: (2012)

La caravana de Gardel : novela /
por: Cruz Kronfly, Fernando
Publicado: (1998)

Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Improving care for women living with HIV: initial outcomes of an integration experience
por: Fink, V, et al.
Publicado: (2012)

La muerte de Carlos Gardel
por: Antunes, António Lobo, 1942-
Publicado: (1997)

La muerte de Carlos Gardel
por: Antunes, António Lobo, 1942-
Publicado: (1997)

Margaret Gardel: At the interface of physics and biology
por: Sedwick, Caitlin
Publicado: (2013)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Gardel, Onetti, y algo más ; ensayos y escritos humorísticos
por: Maggi, Carlos, 1922-
Publicado: (1967)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
por: Tashima, Karen, et al.
Publicado: (2014)

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
por: Minguez, Carlos, et al.
Publicado: (2014)

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
por: Patterson, Patricia, et al.
Publicado: (2014)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe
por: Mocroft, Amanda, et al.
Publicado: (2014)

Facial emotional processing deficits in long-term HIV-suppressed patients
por: Gonzalez-Baeza, Alicia, et al.
Publicado: (2014)

Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials
por: Reeves, Iain, et al.
Publicado: (2014)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients
por: Podzamczer, Daniel, et al.
Publicado: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder
por: Fialho, Renata, et al.
Publicado: (2014)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
por: Montes, Marisa, et al.
Publicado: (2014)

Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: 96 weeks post VERITAS study
por: Trottier, Benoit, et al.
Publicado: (2014)

Efficacy, safety, and lack of interactions with the use of raltegravir in HIV-infected patients undergoing antineoplastic chemotherapy
por: Bañón, Sara, et al.
Publicado: (2014)

Acceptability of PrEP among HIV negative Portuguese men who have sex with men that attended 2014 Lisbon pride fair
por: Miguel Rocha, Luís, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1bqboe6vm61t0uhvh8pg03qn4h